 |
|
|
| |
Willingness to use Long-Acting Injectable Cabotegravir (CAB-LA) or Oral TDF/FTC for Pre-Exposure Prophylaxis (PrEP) During Pregnancy in Africa: Findings from the HPTN-084 Qualitative Sub-study
|
| |
| |
IAS 2023 july 25
Juliane Etima1*, Elizabeth Tolley2, Marie Shoen2, Agatha Bula3, Miria Chitukuta4, Nomhle Khoza5, Emily Namey2, Doreen Kemigisha1, Lerato Makhale5, Mercy Tsidya3, Christina Wong2, Mina Hosseinipour3, Sinead Delany-Moretlwe5 on behalf of the HPTN 084 study team.
1Makarere-Johns Hopkin University Clinical Research Site, Kampala, Uganda*, 2FHI 360, Durham, North Carolina, USA, 3UNC-Project Malawi, Malawi Clinical Research Site, Lilongwe, Malawi, 4University of Zimbabwe-Clinical Trials Research Centre (UZ-CTRC) - Spilhaus Clinical Research Site, Harare, Zimbabwe, 5Wits RHI, University of the Witwatersrand, Johannesburg, South Africa
|
| |
|
|
|
|
|
